Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

10.68 -0.32 (-2.91%)

Streaming Delayed Price Updated: 1:50 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	489,185
Open	11.08
Bid (Size)	10.67 (200)
Ask (Size)	10.70 (400)
Prev. Close	11.00
Today's Range	10.67 - 11.39
52wk Range	2.315 - 15.74
Shares Outstanding	61,758,994
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 17, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-2.2%	-2.2%
1 Month	-0.7%	-0.7%
3 Month	-9.0%	-9.0%
6 Month	+66.6%	+66.6%
1 Year	+188.6%	+188.6%

More News

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

December 10, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active

December 09, 2025

Via AB Newswire

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

December 08, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 08, 2025

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 08, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

December 08, 2025

Via Chartmill

Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗

December 08, 2025

Via Stocktwits

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

December 02, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 18, 2025

Via Benzinga

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

November 03, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

October 29, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

October 22, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

October 14, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?

Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?

The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market

What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?

The current price of Fulcrum Therapeutics, Inc. - Common Stock is 10.68

When was Fulcrum Therapeutics, Inc. - Common Stock last traded?

The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 02/23/26 01:50 PM ET

What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?

The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 659.59M

How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?

Fulcrum Therapeutics, Inc. - Common Stock has 660M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.